Scientific Program

Day 1 :

Biography:

Graduated from Toho Academy of Music in Tokyo, as a pianist and composer, invited by the Boston Symphony, she came to the USA in 1961 as one of the first Japanese women. She then received Master of Art from New York University and finished her Ph.D. credits in Philosophy in 1965. In 1967, Tatsumura then turned to an independent career and became the top International Classical and Cultural Impresario/producer. Until 1992, she produced an average of 2,000 cultural events each year, traveling to more than 140 countries. She was presented with numerous honors for her work from different countries, many for humanitarian causes. She is also well known as
a philanthropist.

She studied Oriental Traditional Medicine of Japan, Korea, Taiwan and China. In 2000 she received her PHD and OMD from the International Academy of Education in Tokyo. She established the Oki-Do Holistic Health Center in 1994 in NY and in 2001 the GAIA Holistic Center (501C3 nonprofit organization) at the wake of 9/11 tragedy, for body mind and spirit, aiming for the noninvasive natural healing methods based on the wisdom of the East. She invented special holistic healing method called ONNETSU THERMOTHERAPY using Heat and 2 vibrations of Sun Far Infra-red (8-10μ) and Terahertz from deep earth planet minerals. The therapy has been widely hailed in hospitals and clinics especially in South Americas. Her invention is patent pending worldwide.

Dr. Kazuko Tatsumura has written numerous articles and several books: e.g. “Overcoming Cancer and Other Diseases in a Holistic Way”, “Your Immune Revolution & Healing Your Healing Power” (with Toru Abo, M.D.). Dr. Kazuko has been invited as a speaker at various World Congresses & International Conferences on Alternative & Holistic Health. She teaches and lectures to MDs and practitioners all over the world.

Abstract:

INTRODUCTION
Onnetsu means comfortable heat. Onnetsu Thermotherapy invented by Dr. Kazuko Tatsumura emits from a special patented ceramic; 1) Heat 2) Precise 8-10μ of vibration of Far Infrared SunRay and 3) Vibration of Terahertz. Dr. Tatsumura is the first in the world to incorporate Terahertz minerals to medical use from active volcanos stones from Japan. Worldwide patent pending.
METHODS
When Onnetsuki is slid over the skin, healthy areas are comfortable, but IF deep tissue is unhealthy or cold, degenerated, patient feels this spot to be ‘hot’. When this ‘hot spot’ is effectively treated with Onnetsu Thermotherapy (Far-Infrared & Terahertz vibrations, and Heat), the hot sensation subsides and the Disease Conditions improve through vibrating water molecules of our deep tissue. Therefore, the Onnetsu Thermotherapy is both a diagnostic and therapeutic. Dr Kazuko’s Onnetsu Thermotherapy is based on four historical and scientific facts:
1. Traditional Japanese Concept of the significance of Body Temperature. Hippocrates also has left quotes on Heat.
2. NASA's finding regarding Far-Infrared vibration from Sun light precise 8-10μ. Also, added is the specific Terahertz vibration of earth minerals from volcanos stones from the depth of our planet earth.
3. Immunology by Dr. Toru Abo, balancing autonomic nervous system to improve condition of white cells; Raising Immunity.
4. Promoting four flows of Energy throughout our body by using acupuncture meridian technique.
RESULT
Some countries (Peru, Cuba & Mexico) are practicing it in the hospitals and clinics. Clinical trials have shown improvements on many diseases: such as asthma, brain, ear & eye problems, cancers, diabetes, rheumatoid arthritis, tuberculosis and various pain conditions. Clinical studies from Cuba and Peru will be presented.
CONCLUSION
Onnetsu Thermotherapy is a new, easy & noninvasive treatment modality to treat difficult chronic medical conditions. Therapy uses Universal Vibrations, Heat, Light, Autonomic Nervous System Balance and Acupuncture Meridian System. Dr. Kazuko has taught Onnetsu Thermotherapy to MDs and health practitioners over past decades throughout the world.

Keynote Forum

Jan Jacques Michiels

Goodheart Institute & Foundation in Nature Medicine & Health, Freedom of Science and Education on behave of the International Collaborations and Academic Research in Myeloproliferative Neoplasms, Netherlands

Keynote: Aspirin Responsive Sticky Platelet Mediated Thrombophilia Caused by Gain of Function Mutations in the Thrombopoietin, JAK2 and MPL Genes in Hereditary and Acquired Essential Thrombocythemia

Time :

Biography:

Dr Jan Jacques Michiels is a Lifestyle Physician and Medical Doctor, MD, educated in Internal Medicine, Hematology, Bloodcoagulation and Vascular Medicine and graduated as PhD at the Erasmus University Medical Center, Rotterdam based on his Thesis Erythromelalgia & Thrombocythemia in 1981. Dr Michiels published more than 400 original manuscripts in peer reviewed international medical journals . Dr Michiels frequently served as Guest Editor and was the Founder and Editor in Chief of Seminars in Vascular Medicine. Dr Michiels is the Founder of the Thrombocythemia Vera Study Group (TVSG) in 1994, the European Working Group on Myeloproliferative Disorders EWG.MPD in 1998 and Myeloproliferative Neoplasms EWG.MPN in 2006 as scientific working groups of the European Hematology Association: EHA. Dr. JJ Michiels is the founder and chair of International Collaboration and Academic Research on Myeloproliferative Neoplasms: ICAR.MPN in 2015 within the HARMONY project of the EHA to collect big data on MPN to improve health and quality of life of MPN patients. Dr Jan Jacques Michiels is the founder and scientific director of the Goodheart Institute & Foundation in Nature Medicine & Health, Rotterdam, The Netherlands, Freedom of Science and Education, Free University Network: FUN Europe. Dr JJ Michiels is co-founder of the Central European Vascular Forum (CEVF) and allied Thrombosis Hemostasis Research Group. Dr Michiels serves as consultant professor in the Hematology and Bloodcoagulation University Hospital Antwerp with special attention to MPN and was co-founder of the VWF-VWD Research Institute of the Hemostasis Thrombosis Laboratory at the Department of Hematology University Hospital, Antwerp. Dr JJ Michiels serves as consultant professor in Hematology and Bloodcoagulation, Comenius University, Bratislava, Slovakia; consultant to the Dutch Society of Internal Medicine and the Ministery of Health Science and Sport and consultant of quality driven Industrial and Pharmaceutical Medicine. Dr JJ Michiels is a editor in chief of 3 Medical Journals and acts as a Guest Editor on request and by self initiation. Dr Michiels is active member of the Belgian, Dutch, German and International Societies on Thrombosis and Haemostasis (ISTH), the European Hematology Association (EHA) and Honory Member of the American Society of Hematology (ASH).

Abstract:

Sticky platelet mediated thrombophiia is featured by aspirin responsive and platelet mediated arteriolar microvas-cular circulation disturbances including erythromelalgia and atypical transient ischemic attacks. The spectrum of aspirin responsive sticky platelet mediated thrombophilia (SPT) in hereditary essential thrombocythemia (HET) due to germline gain of function mutations in the TPO, JAK2 and MPL genes is comparable to the spectrum of SPT in acquired essential thrombocythemia (ET) caused by somatic gain of function mutations JAK2V617F and MPL515. Increase of large platelets in blood smears and large mature megakaryocytes with hyperploid nuclei in a normal cellular bone marrow were diagnostic for autosomal dominant HET and for acquired ET. Evolution of HET and ET into secondary myelofibrosis (MF) belong to the natural history of TPO, JAK2, MPL mutated HET and acquired mutated JAK2V617F and MPL515 mutated acquired ET. In congenital HET caused by heterozygous germline gain of function mutation in the TPO and the JAK2 gene, JAK2V617I and JAK2R564Q, the responses of mutated CD33 and CD34+ cells to TPO are increased, whereas the responses to EPO were normal thereby explaining why HET caused by heterozygous germline TPO and JAK2 mutations are associated with the biological characteristics of ET without PV features. Acquired MPL515 mutated ET has no features of PV, whereas acquired JAK2V617F ET is associated with typical features of PV in blood and bone marrow including low serum EPO and sponta-neous endogenous erythroid colony (EEC) formation. CALR mutated ET and BCR/ABL positive ET are associated with the production of indolent platelet with the absence of sticky platelet mediated thrombophilia and show a rather high tendency of ET evolution into myelofibrosis.

Keynote Forum

Sunil Gomber

UCMS and GTB Hospital, India

Keynote: Optimal prophylactic schedule for FVIII therapy in children with hemophilia A

Time : 11:00

Biography:

Sunil Gomber is the Director & Professor in pediatrics and incharge of pediatric hematology/ oncology in a Government hospital in Delhi, India. He teaches postgraduates in pediatrics besides looking after the patient care.

Abstract:

Background: Prophylaxis in hemophilia is the standard of care. Optimal strategies to conduct prophylaxis in an economically prudent manner have not yet been well-defined in developing countries.

Objective: To compare the efficacy of twice weekly versus thrice weekly Factor VIII prophylactic therapy in prevention of bleeding in children with Hemophilia A & in preserving index joint structures.

Design: Open label randomized clinical trial.

Setting: Tertiary care hospital.

Study duration: April 1, 2017 to March 31, 2018.

Participants: A sample size of 40 children aged less than 18 years with moderate to severe Hemophilia A and not having any measurable inhibitor.

Methods: All children were randomized into two groups A and B followed by detailed history, clinical (HJHS 2.1 score) and radiological examination (Pettersson and ultrasound scores). Prophylaxis started with Group A receiving FVIII at a dose of 10 IU/kg thrice weekly and Group B receiving FVIII at a dose of 10 IU/kg twice weekly. Data regarding bleeding episodes during the study period was collected. All evaluation was repeated at end of study. Main Outcome variable: Annual Bleeding Rate .

Results: Out of 40 children 7 children were excluded since they were having inhibitors against FVIII. 3 chidren were lost to follow up. We analyzed 14 children in twice weekly prophylaxis group and 16 children in thrice weekly prophylaxis group. Statistically insignificant difference was found in median bleeding rate between the thrice weekly prophylaxis group [0.17(0.00- 0.19)] and twice weekly prophylaxis group [0.17(0.00- 0.25)]. The differences between the initial and final HJHS score and ultrasonography score in both the groups improved significantly. The difference in initial and final Pettersson score in both the groups was not significant.

Conclusion: Twice weekly FVIII therapy is an effective, easily administrable and economically prudent prophylactic schedule to prevent long term complications of Hemophilia A.

Speaker
Biography:

Chuanyou has expertise in hematological diseases. Currently,  he is performing  Ph.D. studies at the  Department of Medicine, Karolinska Institutet. During the past years, he has been actively involved in several projects, such as studies of the role of the PDL1 promoter in Hodgkin lymphoma, the role of lipoxygenases in the micro-environment of Hodgkin lymphoma and projects related to how lipoxygenases are acting in CLL and mantle cell lymphoma

Abstract:

We previously reported Hodgkin lymphoma (HL) development in two triplets where all three were homozygotic and had a constitutional deletion in the first intron of the megakaryoblastic leukemia 1 gene (MKL1) ( Bjorkholm M et al, Development of Hodgkin lymphoma in homozygotic triplets with constitutional deletion in MKL1. Blood. 2013;121(23):4807). DNA methylation is thought to play an important role in carcinogenesis. Due to the accordant genome in all triplets, the epigenetic pattern especially the methylation status is of great interest. Four types of cells were isolated from peripheral blood samples of triplets: Naïve B-cells, CD34+ cells, switched Memory B-cells, and marginal zone like B-cells. Subsequently, DNA methylation was analyzed using the Illumina EPIC array with 850.000 CpG site-specific probes. Differences in DNA methylation were found in CD34+ cells, naïve B-cells and marginal zone like B-cells. An overview of the workflow and results is presented in (Fig. 1). In naïve B-cells we found one region on chromosome 19 that differed in DNA methylation, however, one of the HL-affected triplets displayed a hypermethylated region while the other HL-triplet displayed a hypomethylated region as compared to the non-affected triplet. In marginal zone like B-cells, we found 14 genomic regions (two regions had almost complete overlap), spread out on 9 chromosomes, which were all hypermethylated in both HL-affected triplets as opposed to the non-affected triplet. In these regions, genes related to HL and other cancers or hematopoiesis (CYGB; ISM1; KLHL22; MRAS; SNHG16; KDR) were identified. In CD34+ cells we found one region on chromosome 12 where the two HL-affected triplets showed a hypomethylated region as compared to the non-affected triplet. This region was located between gene CCDC65 and FKBP11. These DNA-methylation differences in CD34+ cells and specific B-cell subtypes may contribute to the HL pathogenesis in two of the triplets.

Speaker
Biography:

Seyed Hosein Soleimanzadeh Mousavi currently is a resident of Pediatrics in Zahedan University of Medical Sciences. Seyed Hosein does research in Hematology, Clinical Trials, and Pediatrics.

Abstract:

Introduction:

Blood is a blend of the beauty and the wonders that God has attached to the great life of man and this vital resource is transmitted to the power of mankind. Nowadays, excessive blood intake is one of the most common problems in educational hospitals, which this it raises issues such as the lack of proper distribution of blood products among centres, rising costs, and increasing the volume of blood bank work. With this in mind, programs have been proposed called the Maximum Surgical Blood Ordering Schedule (MSBOS), in which, based on reports from each hospital about the amount of blood used in various surgeries, a special guide for each The center is being prepared.

Method:

This study was a descriptive cross-sectional study. The sampling method was designed in a form that was designed (attached) and, with the coordination of hospital management, this form was distributed among all parts of the hospital, and each section, according to the blood demand and cross-wrist and blood cross-section statistics, determine the wasted and unused blood bag and register it in the appropriate form. This study was performed on 1568 people, of which 562 (35/84%) were blood transfusions.

Findings:

The aim of this study was to determine the pattern for maximal request for surgical surgeries (MSBOS) in elective surgery (elective) in Imam Ali Hospital, Zahedan. This study was performed on 1568 people, of which 562 (35/84%) were under blood transfusion. The mean C/T ratio was 1.61 ± 0.99, the mean TI was 0.61 ± 0.38 and the mean T index was 36.4 ± 30.16%.

Conclusion:

In general, only 55% of the blood is used. The most non-use was in hernia surgery, thyroidectomy, and patients with renal problems. Therefore, according to the results, it is suggested that all patients need to receive blood, indications of blood donation should be done properly by the medical staff and if blood pressure is indicated, blood is requested.

Speaker
Biography:

Qingsheng Xu, MD, PhD currently works in the Department of Neurosurgery in The First Affiliated Hospital, College of Medicine, Zhejiang University in China.

Abstract:

Diffuse midline glioma with histone H3-K27M mutation is a brand-new tumor entity according to 2016 edition of WHO classification. As diffuse midline gliomas are aggressive and incurable brain tumors, conventional treatment can hardly work, leading to the poor outcome of patients. Anlotinib is a newly developed oral small-molecule RTK inhibitor that targets VEGFR1, VEGFR2/KDR, VEGFR3, c-Kit, PDGFR-α, and FGFRs. Anlotinib can inhibit both tumor angiogenesis and tumor cell proliferation. It can inhibit more targets and has a better antiangiogenic activity than other target drugs. Therapeutic efficacy of anlotinib has been proved in advanced NSCLC, advanced STS, metastatic renal cell carcinoma, and advanced medullary thyroid cancer. Only mild side effects were discovered in these studies.

This case report presents a 51-year-old man suffering from diffuse midline glioma with histone H3-K27M mutation. After three cycles of temozolomide , the patient received radiotherapy with total DT of 5400cGy/20F, 200cGy/F, 5F/W, accompanied by chemotherapy of TMZ 75 mg/m2., then therapy with bevacizumab 5 mg/kg, Considering it was inconvenient for bevacizumab injection, we recommended adjusting the treatment plan to oral administration of anlotinib (10 mg qd d1-14, 21 days a cycle) plus TMZ (200 mg/m2, d1-5, 28 days a cycle). After 8 months treatment of anlotinib combined with temozolomide, MRI of this patient showed that the mass was significantly reduced compared to that before targeted therapy.

Our case firstly reported that anlotinib combined with TMZ was used for patients with diffuse midline glioma with histone H3-K27M mutation. Up till now, this patient has survived for 20 months.

Speaker
Biography:

Nahla Osman, MD, MRCP and FRCPath UK works as an assistant professor and consultant haematologist in Menoufia University. She teaches clinical pathology with hematology as main subspeciality. Her research interest includes hemato-oncology.

Abstract:

There has been an increasing evidence of involvement of long non-coding RNA sequences in tumorigenesis (lncRNAs) and is currently being investigated as diagnostic and prognostic markers in a number of malignancies. HOX transcript antisense intergenic RNA (HOTAIR), lncRNA is suggested to play an oncogenic role by enhancing cancer progression, migration and invasion. HOTAIR interacts with and downregulates epigenetic regulators that act as silencer of the epigenetic genes implicated in tumorigenesis.  Aim of the work: to assess HOTAIR lncRNA expression and its prognostic implications in Multiple Myeloma (MM) patients. Subjects and methods: The study involved 62 patients in 3 groups; 24 newly diagnosed MM, 23 patients in complete or very good partial response (CR or VGPR) and 15 patients who had either primary refractory disease (PR) or relapse as well as a 20 healthy controls. The groups were age and sex matched, p was 0.883 and 0.952 respectively. HOTAIR lncRNA expression was measured by quantitative reverse transcription polymerase chain reactions. Results: HOTAIR was significantly upregulated in newly diagnosed and PD/relapse groups (3.13±1.48 and 2.83±1.26 respectively) compared to controls and patients in CR or VGPR (1.02±0.45 and 0.99±0.38 respectively, p<0.001). In addition, higher HOTAIR expression levels were seen in patients with higher percentage of malignant plasma cells (≥ 50 versus < 50%) in bone marrow (2.29±0.67 and 3.97±1.60 respectively, p=0.006) and in those with higher RISS stage (expression levels were 1.85 ± 0.58, 3.06 ± 1.17 and 3.91 ± 1.69 for stages I, II and III respectively p=0.031). Conclusion: HOTAIR expression levels are associated disease activity in MM patients which might reflect a role in pathogenesis. In addition, higher levels are shown to be associated with other well established adverse prognostic factors, thus, HOTAIR can be a prognostic marker and may serve as novel therapeutic target for those patients.

Speaker
Biography:

Bimal Prasad Jit is a Research Fellow in AIPH University, India. His research interests include Cell and Molecular Biology, Infectious Disease, Immunology, Genomics/ Gene Editing, Hematology, Cell Signaling and Hemoglobinopathy. He also trains M.Phil and pre Ph.D students.

Abstract:

Vaso-occlusive crisis (VOC) occurs more frequently during stress in sickle cell disease patients.Epinephrine released during stress increases adhesion of sickled red blood cells (RBCs) to endothelium and to leukocytes, a process mediated through erythrocyte cyclic adenosine monophosphate (cAMP). Increased adhesion of sickled RBCs retards blood flow through the capillaries and promotes vaso-occlusion. Therefore, we examined the association of RBC-cAMP levels with frequency of acute pain episodes in sickle cell disease subjects. Using a case control study design, we measured RBC-cAMP levels, fetal hemoglobin (Hb F), a-thalassemia (a-thal) and other hematological parameters at baseline (sham treated) and after stimulation with epinephrine. The cases consisted of sickle cell disease subjects with three or more acute pain episodes in the last 12 months, and those without a single acute pain episode in the last 12 months were considered as controls. Significantly higher cAMP values were found in cases than the controls, in both sham treated (p<0.001) and epinephrine treated RBCs (p<0.001) by Wilcoxon Rank Sum test. However, significant association of cAMP values was observed both on univariate [odds ratio (OR): 4.8, 95% confidence interval (95% CI): 1.51-15.19, p<0.008) and multivariate logistic regression analyses only in epinephrine treated (OR: 5.07, 95% CI: 1.53-16.82, p<0.008) but not in sham-treated RBCs. In the covariates, Hb F consistently showed protective effects in univariate as well as in multivariate analyses. Frequent acute pain episodes are associated with higher cAMP levels than those with less frequent pain episodes, only after stimulation with epinephrine but not with baseline level.

Speaker
Biography:

Anjali Pandit is a Pediatric Hematology-Oncology & Bone Marrow Transplant Specialist at Nepal Cancer Hospital & Research Center. Her research interests include stem cell transplants, pediatric hematology and cancer.

Abstract:

BACKGROUND: Patients who undergo allo-HSCT are more prone to viral infections or reactivations. HHV-6 infection in post allo-HSCT patients has a varied presentation which include fever, gastrointestinal, respiratory and central nervous system symptoms and myelosuppression. Classically described rash like exanthema subitum may or may not be present.  We aimed to find out the prevalence and clinical manifestations of the HHV-6 reactivation and/or disease in pediatric allo-HSCT patients. 

METHODS: Between January 2017 and June 2018, 54 patients (male-33, female 21) underwent HSCT at our center. Demographic and transplant related details of patients were captured from hospital database. HHV-6 DNA viral load was tested if patient had relevant signs/symptoms. The HHV-6 DNAemia was measured with whole-blood and/or CSF real-time quantitative polymerase chain reaction (PCR) technique.  

RESULTS: 

A total of 54 consecutive patients underwent allogeneic HSCT during the study period. Donors were HLA-matched related-30, haploidentical-17 and matched unrelated-7. The source of stem cells was peripheral blood in 50 patients and bone marrow in 4 patients. Three patients (5.5%) had HHV-6 reactivation. One patient had persistent fever and pancytopenia from D+20. Second patient presented with generalized tonic clonic seizure on D+60. Third patient had persistent fever with maculopapular rash over extremities and face from D+30. Median time of detection was day 30 (range, 15-60 days).  Two patient had HHV 6 viremia detected in blood and one in CSF. Out of these 1 patient had coexistent cytomegalovirus (CMV) reactivation. All these patients were treated with intravenous (IV) gancyclovir (GCV) at the dose of 5 mg/kg every 12 hours. Two patients showed resolution of symptoms in 3 to 4 days. HHV-6 became undetectable in 1 week after initiation of treatment. The patient who had coexisting CMV and HHV-6 developed severe aplastic bone marrow post IV GCV which required discontinuation of treatment and the patient eventually died. 

CONCLUSION: Our findings point out that HHV 6 infection is rare but dreaded complication in post allo-HSCT patients. Clinicians need to have high index of suspicion as the presentation can be varied. Early diagnosis and treatment can lead to better outcomes in this patient population. 

Speaker
Biography:

Awa Carimo is an internist working in Maputo Central Hospital, Mozambique, she has completed her Master thesis from Faculty of Medicine Lisbon University. He has published 3 papers in reputed journals.

She worked in Nephrology department from 2011, in Maputo Private Hospital, as a dialysis supervisor.

She works in the Mozambican Ministry of Health as a member of national technical group of hepatitis and in the group of revising the national list of essential medicines.

She is an assistant teacher in Medicine Faculty, in Universidade Eduardo Mondlane as well as in Instituto Superior de Ciências e Tecnologia de Moçambique.

Abstract:

The prevalence of hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection in Mozambique is one of the highest in the world, though in spite of this the prevalence of occult hepatitis B infection (OBI) is unknown. The clinical impact of OBI is unclear, but it’s been related the increase of the risk of HBV transmission through blood transfusion, organ and bone marrow transplantation, HBV reactivation  after immunosuppression and risk of progression to chronic liver disease and hepatocellular carcinoma. The aim of this study was to investigate the prevalence of OBI among antiretroviral (ART) naïve HIV-positive patients in Mozambique.

Methodology: A cross-sectional study was conducted in two health facilities within Maputo city. All ART-naive HIV seropositive patients attending outpatient clinics between June and October 2012 were consecutively enrolled. Blood samples were drawn from each participant and used for serological measurement of HBV surface antigen (HBsAg), antibodies against HBV surface antigen (anti-HBs) and antibodies against core antigen (anti-HBc) using ELISA. Quantification of HBV DNA was performed by real time PCR. A questionnaire was used to obtain demographics and clinical data. Findings: Of the 518 ART-naive HIV-positive subjects enrolled in the study, 90.9% (471/518) were HBsAg negative. Among HBsAg negative, 45.2% (213/471) had isolated anti-HBc antibodies, and the frequency of OBI among patients with anti-HBc alone was 8.3% (17/206). OBI was not correlated with transaminases levels. A total of 11.8% of patients with OBI presented elevated HBV DNA level. Frequency of individuals with APRI score > 2 and FIB-4 score > 3.25 was higher in patients with OBI as compared not exposed, immune and anti-HBc alone patients. Conclusion: Our data demonstrate for the first time that OBI is prevalent among HIV patients in Mozambique, and will be missed using the commonly available serological assays that measures HBsAg.

Day 2 :

Biography:

Prof Dr.Niranjan Bhattacharya holds a MD in Obstetrics and Gynaecology, MS in General Surgery and a DSc in Developmental Immunology. His principal specializations are cell and tissue therapy. Has presented Invited lectures in several international universities (More than 150) and institutions. Has published widely in international and national journals on cord blood and regenerative medicine; is the co-editor of five books on the subject published by Springer Nature with Prof Phillip Stubblefield, Emeritus Prof Ob/Gyn, Boston University/Harvard University etc. Currently, working as Chair Professor and Head of the Department, Regenerative Medicine and Translational Science, and Director General, first Public Cord Blood Bank in India, Calcutta School of Tropical Medicine, Kolkata. Globally Cited among top five global cord blood influencers by BioInformant.

Abstract:

There are about 100 million births in the world annually at a conservative estimate. In India, there are over 20 million births per annum, which means that over 20 million placentas are discarded every year as waste. One of the products of the placenta is cord blood; it has immense potentials. An estimated 8,785,000 Litres of cord blood is produced globally per year if an average of 84-90 ml/placenta collection is assumed. Our group of medical scientists and clinicians transfused ABO screened and HLA matched randomized fetal blood in cases of anemia resulting from malaria, diabetes, thalassemia, leprosy, rheumatoid arthritis, tuberculosis, malignancy, AIDS, and found it not only to be safe but perhaps providing additional benefits that need further study. In parts of the world where research is ongoing, a microscopic section of cord blood’s mononuclear cells (0.01% nucleated cells) is used for transplantation purposes, while the rest, i.e., 99.99% is discarded. But the discarded part has many potential uses. Cord blood is free from infection, hypoantigenic in nature, has an altered metabolic profile, is enriched with growth factors and cytokine filled plasma and has a potentially higher oxygen carrying capacity than adult blood The blood volume of a fetus at term is around 80-85 ml/kg. The placental vessel at term contains approximately 150 ml of cord blood. Cord blood contains three types of hemoglobin, HbF (major fraction), HbA (15-40%) and HbA2 (trace amounts). HbF, which is the major component, has a greater oxygen binding affinity than HbA. Our group of medical scientists and clinicians conducted over 1260 cord blood transfusions with safe outcomes in all cases, as indicated in our published studies, from 1999 till date (follow-up) in children and adults for various indications. Not a single case of immediate or delayed immunological or non-immunological reaction was reported.

Speaker
Biography:

Abstract:

Oxidative stress means a state there is imbalance between the oxidizing action and the reducing action due to reactive oxygen species (ROS) in a living body, resulting in the oxidizing action becoming dominant.  Oxidative stress arises as the balance between production and removal is disrupted through excessive production of ROS and impairment of the antioxidant system.  Oxidative stress has been reported to be involved in the onset and progress of various diseases.  Characteristics of Type 2 diabetes are insulin secretion failure and insulin resistance, but it seems that oxidative stress is greatly involved in insulin secretion failure.  In the insulin secretion-inducing β cells of Langerhans islets in the pancreas, the amount of superoxide dismutase (SOD), which is representative of the ROS elimination system, is small and resistance to oxidative stress is considered to be weak. Regarding cancer, it is well known that chronic inflammatory conditions increase the risk of carcinogenesis.  Cells such as neutrophils and macrophages are activated in the inflammation area leading to increase in production of active oxygen and nitric oxide.  These free radicals cause DNA mutation and cell proliferation thereby promoting cancer development.  When chronic inflammation is present, cancer develops more easily. 

Electronic water, which was developed to generate electron in water, was consumed for three weeks, after meals, between meals and before sleeping 6 times a day, and according to the test subjects' possible time periods.  The amount of drinking water was 750-1000 mL, and BAP and d-ROMs checks for all cases were carried out at 4:30 pm.  The results of cancer patients and diabetes patients were seen as attached.

As a result, the d-ROMs value in the degree of oxidative stress has reduced, and the BAP value, which is an indicator of plasma antioxidant capacity, has improved significantly.

Speaker
Biography:

Haibo Mou currently works in the Department of Medical Oncology, Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang Province, China.

Abstract:

Introduction:
Hepatocellular carcinoma (HCC) is a highly malignant tumor around the world, the most frequent site of extrahepatic metastasis in HCC patients is the lungs, and Anlotinib is a novel oral oral multi-targeted receptor tyrosine kinase inhibitor that is synthetized to primarily inhibit a group of newly identified kinase, such as VEGFR2/3,FGFR1-4,PDGFR α/β, which plays an important role in tumor progression. It has been approved for treatment of advanced none-small cell lung cancer, small cell lung cancer, soft tissue sarcoma in China. Here we discuss a case of Anlotinib for the treatment of advanced hepatocellular carcinoma with lung metastasis.
Case Report:
The patient is a 56-year-old man with a history of chronic hepatitis B and 40 years drinking history, He presented with a detectable liver lesion which was clinically diagnosed as HCC in September 2014, after surgery for hepatocellular carcinoma, he was found left lung metastases in 2015. Then the patient was suggested to take Sorafenib until 2018,.after the new lesion be found in the right lung, he was treated with Nivolumab 140 mg PD-1 immunotherapy checkpoint inhibitor for four cycles, After the failure of Nivolumb, he received the combination of PD-1 Nivolumab 140 mg and CTLA-4 Ipilimumab 46 mg q2w for four cycles. But the patient couldn’t acquire benefits from dual-immune checkpoint inhibition, then the patient was given oral Anlotinib 10 mg d1-14 q3w from October 2018.
The CT scan performed after Anlotinib therapy 1 cycle (21 days), exhibited that the lesions in the lung were much smaller, the patient was determined to have partial response. The progression-free survival time is 7 months, at last, the patient died for the pulmonary infection on April 2019.
Discussion:
There are no specific treatment options for hepatocellular carcinoma with lung metastasis other than the recommendations under guidelines for advanced HCC. We found that the Anlotinib for the lung metastasis with HCC showed excellent efficacy, Anlotinib extended the life expectancy significantly for this patient. To the best of our knowledge, this is the first case report of Anlotinib in the treatment of HCC with lung metastasis.

Speaker
Biography:

Dr. Khin La Pyae Tun is a pathologist who works at Blood Research Division , Department of Medical Research, Myanmar. She has been working in research field for about 10 years . After getting her master degree in pathology, her great interest in haematology leads her to do research work focus on it. Since Myanmar is the developing county , diagnosis of haematological malignancy still rely mainly on haemato-clinical findings. Her wish to study gene muatation that can contribute towards the clinical diagnosis and management of the patients along with her research findings. 

Abstract:

Myeloproliferative neoplasms (MPNs) is a group of clonal haematopoietic stem cell disorders characterized by the proliferation of one or more myeloid cell lineages. According to WHO classification, the Janus associated kinase 2 (JAK2) V617F mutation is the one of the major diagnostic criteria in BCR-ABL1 negative myeloproliferative neoplasms .The aim of this study is to detect the JAK2 (V617F) mutation in patients with myeloproliferative neoplasms to get accurate diagnosis and proper management. A total of 90 clinically diagnosed MPN patients attending to Department of Clinical Haematology ,Yangon General Hospital were enrolled in this study. The mean age was 53.4 ± 14 years which ranged from 16 to 81 years old and male and female ratio was 2.4:1.  The identification of JAK2 (V617F) point mutation was found to be positive in 44/90 MPN patients (48.9%).  According to MPN subtypes, the JAK2  mutation positivity  was found  in 19 out of 46 polycythemia vera patients ( 41.3 %), 17 out of 25 essential thrombocythemia patients (68%), 8 out of 15  primary myelofibrosis patients (53.3%),  0 of 4 others myeloproliferative neoplasms (0%).  Confirmation of each of nine JAK2 mutation positive and negative samples were done by Sanger sequencing. The arterial or venous thrombotic attack was found in  32 /44 JAK 2 mutation positive cases (72.7%) and 12 /44 JAK2 mutation negative cases (27.3 %) .The association between  thrombotic attack and presence of JAK2 mutation was statistically significance with p=0.000. In our study, prevalence of JAK2 (V617F) mutation was lower in polycythemia vera patients compared to other studies which showed over 90% positivity of JAK2 mutation in PV . It might be due to the secondary polycythemia in which the chronic heavy smoking is the common cause. The diagnosis of myeloproliferative neoplasms mainly relies on the molecular genetics according to WHO classification. The Allele specific PCR reaction  is sensitive, simple test and relatively cost effective. Therefore, the identification of JAK2 (V617F) somatic point mutation should be implemented as a routine diagnosis procedure for patients with chronic and suspected myeloproliferative neoplasms.